Barclays Begins Coverage on Editas Medicine, Inc. (EDIT) With An Initial Rating Of “Overweight” – Finance Daily
|
Barclays Begins Coverage on Editas Medicine, Inc. (EDIT) With An Initial Rating Of “Overweight”
Finance Daily CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cpf1 (CRISPR from Prevotella and Francisella 1), bound to a guide RNA molecule designed to recognize a particular … |
